Mexico’s Ministry of Health and state-owned BIRMEX awarded 673 codes worth MXN 34.4 billion in the third public tender of the 2027–2028 consolidated purchase, bringing coverage to about 90% of …
Mexico’s Ministry of Health and state-owned BIRMEX awarded 673 codes worth MXN 34.4 billion in the third public tender of the 2027–2028 consolidated purchase, bringing coverage to about 90% of …
Novo Nordisk began distributing oral semaglutide 25 mg (Wegovy tablets) in Mexico’s private market on November 11, after COFEPRIS approval in August. The same day, an update to the national …
Moderna and Laboratorios Liomont signed a license, distribution and supply agreement for Mexico’s COVID-19 vaccines, with phased messenger RNA (mRNA) technology transfer, as Mexico’s state-owned BIRMEX awarded Liomont an open …
A MXN 3,510.2 million inter-institutional compensation line in Mexico’s 2027 budget proposal is meant to finance the Servicio Universal de Salud (SUS) as it starts in 2027, even as IMSS …
A Mexican health-systems researcher warns that the new scheme could generate more demand than the social-security institutions can absorb, and that far more public investment is indispensable, though not sufficient, …
Mexico’s pharmaceutical and medical-device industry chamber, Canifarma, says 650–700 medicine listings have been removed from Mercado Libre under a June 2026 brand-protection agreement, and warns that public health-sector medicines are …
Mexico’s public mental health system is severely under-resourced even as nearly five million people in Mexico live with a mental health condition. The Instituto Mexicano del Seguro Social (IMSS) fields …
Mexico’s Cofepris has granted marketing authorization for lenacapavir as twice-yearly injectable pre-exposure prophylaxis against HIV, placing Mexico among a small group of countries with regulatory access to the long-acting prevention …
Donanemab is now infused in a Mexican public hospital. Lilly’s 2026 target: 30 patients — the gap between innovation and the system, in one number.
Mexico’s Cofepris has established an abbreviated registration pathway recognising ANVISA evaluations, with a 45-business-day resolution ceiling — accelerating market entry for manufacturers already cleared in Brazil.
You must be logged in to post a comment.